{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:33:26Z","timestamp":1787020406332,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:00:00Z","timestamp":1576108800000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Ministry of Health & Welfare, Republic of Korea","award":["HI17C0911"],"award-info":[{"award-number":["HI17C0911"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Altern Med"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>ChondroT<\/jats:italic>\n                      , a new herbal medication, consists of\n                      <jats:italic>Angelica grosseserrata<\/jats:italic>\n                      Maxim.,\n                      <jats:italic>Lonicera japonica<\/jats:italic>\n                      Thunb.,\n                      <jats:italic>Angelica gigas<\/jats:italic>\n                      Nakai,\n                      <jats:italic>Clematis terniflora<\/jats:italic>\n                      var.\n                      <jats:italic>manshurica<\/jats:italic>\n                      (Rupr.) Ohwi, and\n                      <jats:italic>Phellodendron amurense<\/jats:italic>\n                      Rupr. (6:4:4:4:3). Our previous studies have shown that\n                      <jats:italic>ChondroT<\/jats:italic>\n                      exhibits significant anti-arthritic and anti-inflammatory effects. In this study, we aimed to assess the toxicological safety assessment of\n                      <jats:italic>ChondroT.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study was designed to assess the safety of\n                      <jats:italic>ChondroT<\/jats:italic>\n                      after repeated oral administration.\n                    <\/jats:p>\n                    <jats:p>\n                      Male and female Sprague-Dawley rats were treated with\n                      <jats:italic>ChondroT<\/jats:italic>\n                      at oral doses of 0, 500, 1000, and 2000 mg\/kg for 13 weeks. Mortality, clinical signs, body weight changes, food consumption, ophthalmological findings, urinalysis, hematological and blood-chemical parameters, necropsy findings, organ weights, and histological markers were recorded throughout the study period. Rats were also monitored for an additional 4 weeks to determine the recovery time.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No death occurred and no significant changes in food consumption, ophthalmologic findings, and urinalysis were found. Although there were alterations in clinical signs, body weights, hematological parameters, blood-chemical parameters, necropsy findings, organ weights, and histological markers, they were not considered to be toxicologically significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The results suggest that the no-observed adverse effects level (NOAEL) was 2000 mg\/kg\/day for the test substance.\n                      <jats:italic>ChondroT,<\/jats:italic>\n                      a new complex herbal medication composed of five plants, can therefore be used safely at the NOAEL.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12906-019-2773-4","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T04:21:31Z","timestamp":1576210891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A 13-Week Repeated Oral Dose Toxicity Study of ChondroT in Sprague-Dawley Rats"],"prefix":"10.1186","volume":"19","author":[{"given":"Jiwon","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiljoon","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5332-6165","authenticated-orcid":false,"given":"Jihoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanhun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsu","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myeongkyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngran","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Seob","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seon-Jong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,12]]},"reference":[{"key":"2773_CR1","first-page":"315","volume-title":"CheongKangEuiGam","author":"YH Kim","year":"2001","unstructured":"Kim YH, Lee JH. CheongKangEuiGam. Seoul: Seongbosa; 2001. p. 315."},{"key":"2773_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1472-6882-13-47","volume":"13","author":"BR Jeoung","year":"2013","unstructured":"Jeoung BR, Lee KD, Na CS, Kim YE, Kim B, Kim YR. Ganghwaljetongyeum, an anti-arthritic remedy, attenuates synoviocyte proliferation and reduces the production of proinflammatory mediators in macrophages: the therapeutic effect of GHJTY on rheumatoid arthritis. BMC Complement Altern Med. 2013;13:47\u201352.","journal-title":"BMC Complement Altern Med."},{"key":"2773_CR3","doi-asserted-by":"publisher","unstructured":"Choi W, Choi CH, Kim YR, Kim SJ, Na CS, Lee H. HerDing: herb recommendation system to treat diseases using genes and chemicals. Database-Oxford. 2016;2016:baw011. https:\/\/doi.org\/10.1093\/database\/baw011.","DOI":"10.1093\/database\/baw011"},{"key":"2773_CR4","first-page":"1","volume":"2016","author":"W Kim","year":"2016","unstructured":"Kim W, Park S, Choi C, Kim YR, Park I, Seo C, et al. Evaluation of Anti-Inflammatory Potential of the New Ganghwaljetongyeum on Adjuvant-Induced Inflammatory Arthritis in Rats. Evid Based Complement Alternat Med. 2016;2016:1\u201310.","journal-title":"Evid Based Complement Alternat Med"},{"key":"2773_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/8565132","volume":"2018","author":"KJ Bae","year":"2018","unstructured":"Bae KJ, Jeong JW, Choi CH, Won JY, Kim TG, Kim YR, et al. Antiosteoarthritic Effects of ChondroT in a Rat Model of Monosodium Iodoacetate-Induced Osteoarthritis. Evid Based Complement Alternat Med. 2018;2018:1\u201311.","journal-title":"Evid Based Complement Alternat Med"},{"key":"2773_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12906-018-2149-1","volume":"18","author":"JW Jeong","year":"2018","unstructured":"Jeong JW, Bae KJ, Kim SG, Kwak DW, Moon Y-J, Choi CH, et al. Anti-osteoarthritic effects of ChondroT in a rat model of collagenase-induced osteoarthritis. BMC Complement Altern Med. 2018;18:131\u201340.","journal-title":"BMC Complement Altern Med"},{"key":"2773_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12906-016-1211-0","volume":"16","author":"JU Park","year":"2016","unstructured":"Park JU, Kim SJ, Na CS, Choi C, Seo CS, Son JK, et al. Chondroprotective and anti-inflammatory effects of ChondroT, a new complex herbal medication. BMC Complement Altern Med. 2016;16:213\u201323.","journal-title":"BMC Complement Altern Med"},{"key":"2773_CR8","doi-asserted-by":"crossref","unstructured":"Oh DR, Kim JR, Choi CY, Choi C hun, Na C su, Kang BY, et al. Effects of ChondroT on potassium Oxonate-induced Hyperuricemic mice: downregulation of xanthine oxidase and urate transporter 1. BMC Complement Altern Med. 2019;19:10\u201317.","DOI":"10.1186\/s12906-018-2415-2"},{"key":"2773_CR9","doi-asserted-by":"publisher","first-page":"e0170","DOI":"10.1097\/MD.0000000000010170","volume":"97","author":"S Lee","year":"2018","unstructured":"Lee S, Kim SJ. Efficacy and safety of ChondroT on knee-osteoarthritis: Protocol for a 8-week, randomized, double-blind, placebo-controlled, multicenter therapeutic exploratory clinical trial. Medicine Baltimore. 2018;97:e0170.","journal-title":"Medicine Baltimore"},{"key":"2773_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.18325\/jkmr.2018.28.2.61","volume":"28","author":"YH Lim","year":"2018","unstructured":"Lim YH, Jeong JW, Kim SG, Kim JH, Kim SJ. DRF and Single Dose Oral Toxicity Study of ChondroT in Rat. J Korean Med Rehabil. 2018;28:61\u201372.","journal-title":"J Korean Med Rehabil"},{"key":"2773_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/ard.2007.079764","volume":"67","author":"J Dequeker","year":"2008","unstructured":"Dequeker J, Luyten FP. The history of osteoarthritis-osteoarthrosis. Ann Rheum Dis. 2008;67:5\u201310.","journal-title":"Ann Rheum Dis"},{"key":"2773_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1177\/1759720X12437354","volume":"4","author":"T Neogi","year":"2012","unstructured":"Neogi T. Clinical significance of bone changes in osteoarthritis. Ther Adv Musculoskel Dis. 2012;4:259\u201367.","journal-title":"Ther Adv Musculoskel Dis"},{"key":"2773_CR13","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1136\/ard.2005.039263","volume":"64","author":"PG Conaghan","year":"2005","unstructured":"Conaghan PG, Vanharanta H, Dieppe PA. Is progressive osteoarthritis an atheromatous vascular disease? Ann Rheum Dis. 2005;64:1539\u201341.","journal-title":"Ann Rheum Dis"},{"key":"2773_CR14","first-page":"10","volume":"27","author":"RD Altman","year":"1991","unstructured":"Altman RD. Criteria for classification of clinical osteoarthritis. J Rheumatol Suppl. 1991;27:10\u20132.","journal-title":"J Rheumatol Suppl"},{"key":"2773_CR15","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(11)60243-2","volume":"377","author":"JW Bijlsma","year":"2011","unstructured":"Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011;377:2115\u201326.","journal-title":"Lancet"},{"key":"2773_CR16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1136\/ard.2009.113100","volume":"69","author":"W Zhang","year":"2010","unstructured":"Zhang W, Doherty M, Peat G, Bierma-Zeinstra MA, Arden NK, Bresnihan B, et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis. 2010;69:483\u20139.","journal-title":"Ann Rheum Dis."},{"key":"2773_CR17","first-page":"836","volume":"64","author":"SR Santos","year":"2009","unstructured":"Santos SR, Rangel ET, Lima JCS, Silva RM, Lopes L, Noldin VF, et al. Toxicological and phytochemical studies of Aspidosperma subincanum Mart. stem bark Guatambu. Pharmazie. 2009;64:836\u20139.","journal-title":"Pharmazie."},{"key":"2773_CR18","first-page":"47","volume":"2","author":"HY Son","year":"1998","unstructured":"Son HY, Kim YB, Ha CS, Kang BH. Histopathological observation of spontaneous testicular atrophy in Sprague-Dawley rat. Korean J Vet Pathol. 1998;2:47\u201351.","journal-title":"Korean J Vet Pathol."},{"key":"2773_CR19","unstructured":"Boorman GA. Pathology of the Fischer rat: reference and atlas. San Diego: Academic Press; 1990."},{"key":"2773_CR20","doi-asserted-by":"crossref","unstructured":"Pritam SS, James AP, Jerry FH, Chirukandath G. Toxicologic Pathology: Nonclinical Safety Assessment. Boca Raton: CRC Press; 2013. p. 77\u201396.","DOI":"10.1201\/b13783-6"},{"key":"2773_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1177\/0300985809353311","volume":"47","author":"HY Lee","year":"2010","unstructured":"Lee HY, Na YR, Seok SH, Baek MW, Kim DJ, Park SH, et al. Spontaneous Basal Cell Carcinoma in a 7-Week-Old Sprague-Dawley Rat. Vet Pathol. 2010;47:137\u20139.","journal-title":"Vet Pathol"},{"key":"2773_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/019262339202000303","volume":"20","author":"GM Zwicker","year":"1992","unstructured":"Zwicker GM, Eyster RC, Sells DM, Gass JH. Spontaneous Skin Neoplasms in Aged Sprague-Dawley Rats. Toxicol Pathol. 1992;20:327\u201340.","journal-title":"Toxicol Pathol"},{"key":"2773_CR23","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","volume":"22","author":"RS Shannon","year":"2008","unstructured":"Shannon RS, Minakshi N, Nihal A. Dose translation from animal to human studies revisited. FASEB J. 2008;22:659\u201361.","journal-title":"FASEB J"},{"key":"2773_CR24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/molecules23010217","volume":"23","author":"J Choi","year":"2018","unstructured":"Choi J, Ryu SJ, Kim KJ, Kim HM, Chung HC, Lee BY. Single, 14-Day, and 13-Week Repeated Dose Toxicity Studies of Daily Oral Gelidium elegans Extract Administration to Rats. Molecules. 2018;23:217\u201335.","journal-title":"Molecules"}],"container-title":["BMC Complementary and Alternative Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-019-2773-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12906-019-2773-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-019-2773-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T19:22:18Z","timestamp":1607628138000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-019-2773-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2773"],"URL":"https:\/\/doi.org\/10.1186\/s12906-019-2773-4","relation":{},"ISSN":["1472-6882"],"issn-type":[{"value":"1472-6882","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"26 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study protocol was reviewed and approved (IAC2015-0797) by the Institutional Animal Care and Use Committee (IACUC) of KTR Hwasun based on the Animal Protection Act [Enforcement Date: 2015-01-20; No. 13023(2015-01-20, partial revision)] and the Laboratory Animal Act [Enforcement Date: 2013-07-30; No. 11987(2013-07-30, partial revision)].This study was conducted in accordance with the guideline for toxicity testing of pharmaceuticals, MFDS (Notification No. 2014-136, 2014-07-30).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"367"}}